P Mismetti

Publications (3)6.79 Total impact

• Article: [In Process Citation].

  C Chauleur, C Fanget, P Mismetti
  Journal des Maladies Vasculaires 03/2013; 38(2):86-7. · 0.54 Impact Factor
• Article: [Latest developments on risk factors and prophylaxis of thromboembolic disease in obstetrics].

  C Chauleur, J-C Gris, P Seffert, P Mismetti
  [show abstract] [hide abstract]
  ABSTRACT: Venous thromboembolic disease and placental vascular pathology are responsible for an important maternal and foetal morbi-mortality with a modification of the hemostasis parameters. As these biological factors combined with particular clinical features can increase or reduce the risk of occurrence of these diseases, knowing the risk factors would help to prevent problems during the pregnancy. Several antithrombotic therapies exist, including very recent ones. Furthermore, a lot of recommendations are available in the literature. A lot of data are thus at our disposal but their synthesis is necessary to be really useful. We review here the risk factors, therapies and recommendations to help improve the management of these women.
  Gynécologie Obstétrique & Fertilité 04/2012; 40(5):301-7. · 0.52 Impact Factor
• Article: Some hemostasis variables at the end of the population distributions are risk factors for severe postpartum hemorrhages.

  C Chauleur, E Cochery-Nouvellon, E Mercier, G Aya, P Fabbro-Peray, P Mismetti, G Lissade-Lavigne, J-C Gris
  [show abstract] [hide abstract]
  ABSTRACT: Severe postpartum hemorrhages (PPH) represent a significant cause of maternal morbidity/mortality, but little is known about its hemostasis-related risk factors. Among the 32 463 women enrolled in the NOHA First cohort, 317 developed severe PPH (S-PPH group), 1269 non-severe PPH (NS-PPH group) and the remaining individuals were considered as control women (C group). We performed a case-control study, including 317 triplets of women allocated from the three groups that shared the same clinical characteristics as the S-PPH group. From values obtained 6-9 months after delivery, low (but not-deficient) levels of fibrinogen, von Willebrand factor (VWF) antigen, factor (F) XI, platelet CD42b, TRAP-induced increase of platelet CD41a and high values of serum residual prothrombin activity or closure aperture times using the collagen-ADP cartridge on the PFA-100 system, and blood group O, were independently associated with a significant risk of severe PPH. Being positive for at least two of these eight variables was found in 1.6%, 3.5% and 20.8% of the women from the C, the NS-PPH and the S-PPH groups, respectively, the odds ratio for S-PPH in such a case being 16.4, 95%CI (6.5-41), P < 0.0001. Women with some hemostasis-related variables at the low or high end of the population distributions are prone to the severe forms of PPH. Clinical trials will allow us to know if acting on these risk factors can lower the clinical severity of PPH.
  Journal of Thrombosis and Haemostasis 10/2008; 6(12):2067-74. · 5.73 Impact Factor